Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Published:2014-02-13 Issue:7 Volume:123 Page:985-991
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ludwig Heinz¹,Kasparu Hedwig²,Leitgeb Clemens¹,Rauch Elisabeth¹,Linkesch Werner³,Zojer Niklas¹,Greil Richard⁴,Seebacher Adelheid⁵,Pour Ludek⁶,Weißmann Adalbert¹,Adam Zdeněk⁶

Affiliation:

1. Department of Medicine I, Wilhelminenspital, Vienna, Austria;

2. Department of Internal Medicine, Hospital Elisabethinen, Linz, Austria;

3. Department of Hematology, Medical University, Graz, Austria;

4. Department of Internal Medicine III, Hospital Salzburg, Salzburg, Austria;

5. Department of Hemato-oncology, Hanusch Krankenhaus, Vienna, Austria; and

6. University Hospital, Brno, Czech Republic

Abstract

Key PointsBendamustine-bortezomib-dexamethasone is active and well tolerated in relapsed/refractory myeloma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/7/985/538250/985.pdf

Reference30 articles.

1. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.;Petrucci;Br J Haematol,2013

2. Bendamustine: a new look at an old drug.;Kalaycio;Cancer,2009

3. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.;Roué;Clin Cancer Res,2008

4. Bendamustine.;Balfour;Drugs,2001

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring;Immunologic Research;2024-09-10

2. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma;Laboratory Medicine;2024-07-22

3. Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies;Cancer Chemotherapy and Pharmacology;2024-06-15

4. Comparable Efficacy of Oral Bendamustine versus Intravenous Administration in Treating Hematologic Malignancies;2024-01-16

5. Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience;Hematology Reports;2023-08-02